

## **AVXS-101 and Nusinersen for Spinal Muscular Atrophy: Effectiveness and Value**

### **Key Stakeholder Organizations**

ICER has identified the following organizations as key stakeholders for its review on AVXS-101 and nusinersen for spinal muscular atrophy. ICER has invited or received input from the following organizations, and welcomes suggestions from the broader community on additional organizations to add to this list. ICER also receives input from independent patients and clinicians and invites the public to submit recommendations for key stakeholders in these categories. None of these individuals or organizations are responsible for the final contents of ICER's report or should be assumed to support any part of the report, which is solely the work of the ICER team and its affiliated researchers.

For a complete list of key dates and opportunities for input on this project, please visit [ICER's website](#).

- American Academy of Neurology
- American Society of Human Genetics
- AveXis/Novartis
- Blue Cross Blue Shield of Massachusetts
- Biogen
- Connecticut State Department of Social Services
- CureSMA
- Department of Vermont Health Access
- Gwendolyn Strong Foundation
- Miracle for Madison & Friends
- Parent Project Muscular Dystrophy
- SMA Angels Charity
- SMA Foundation
- World Muscle Society